Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease
Isabelle Arnoux, Michael Willam, Nadine Griesche, Jennifer Krummeich, Hirofumi Watari, Nina Offermann, Stephanie Weber, Partha Narayan Dey, Changwei Chen, Olivia Monteiro, Sven Buettner, Katharina Meyer, Daniele Bano, Konstantin Radyushkin, Rosamund Langston, Jeremy J Lambert, Erich Wanker, Axel Methner, Sybille Krauss, Susann Schweiger, Albrecht Stroh, Isabelle Arnoux, Michael Willam, Nadine Griesche, Jennifer Krummeich, Hirofumi Watari, Nina Offermann, Stephanie Weber, Partha Narayan Dey, Changwei Chen, Olivia Monteiro, Sven Buettner, Katharina Meyer, Daniele Bano, Konstantin Radyushkin, Rosamund Langston, Jeremy J Lambert, Erich Wanker, Axel Methner, Sybille Krauss, Susann Schweiger, Albrecht Stroh
Abstract
Catching primal functional changes in early, 'very far from disease onset' (VFDO) stages of Huntington's disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex - one of the first regions affected in premanifest Huntington's disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the antidiabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington's disease pathogenesis long before the onset of clinical symptoms.
Keywords: C. elegans; Huntington disease; cortical microcircuits; in vivo calcium imaging; metformin; mouse; neuronal hyperactivity; neuroscience.
Conflict of interest statement
IA, MW, NG, JK, HW, NO, SW, PN, CC, OM, SB, KM, DB, KR, RL, JL, EW, AM, SK, SS, AS No competing interests declared
© 2018, Arnoux et al.
Figures
References
- Brooks S, Higgs G, Jones L, Dunnett SB. Longitudinal analysis of the behavioural phenotype in Hdh(CAG)150 Huntington's disease knock-in mice. Brain Research Bulletin. 2012;88:182–188. doi: 10.1016/j.brainresbull.2010.05.004.
- Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686–1689. doi: 10.1126/science.1162844.
- Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A. Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. PNAS. 2012;109:8740–8745. doi: 10.1073/pnas.1206171109.
- Busche MA, Kekuš M, Adelsberger H, Noda T, Förstl H, Nelken I, Konnerth A. Rescue of long-range circuit dysfunction in Alzheimer's disease models. Nature Neuroscience. 2015;18:1623–1630. doi: 10.1038/nn.4137.
- Busche MA, Konnerth A. Impairments of neural circuit function in Alzheimer's disease. Philosophical Transactions of the Royal Society B: Biological Sciences. 2016;371:20150429. doi: 10.1098/rstb.2015.0429.
- Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013;153:228–239. doi: 10.1016/j.cell.2013.02.035.
- Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. The Journal of Neuroscience. 2003;23:961–969. doi: 10.1523/JNEUROSCI.23-03-00961.2003.
- Clabough EB. Huntington's disease: the past, present, and future search for disease modifiers. The Yale Journal of Biology and Medicine. 2013;86:217–233.
- Crook ZR, Housman D. Huntington's disease: can mice lead the way to treatment? Neuron. 2011;69:423–435. doi: 10.1016/j.neuron.2010.12.035.
- Damiano M, Galvan L, Déglon N, Brouillet E. Mitochondria in Huntington's disease. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease. 2010;1802:52–61. doi: 10.1016/j.bbadis.2009.07.012.
- Demir U, Koehler A, Schneider R, Schweiger S, Klocker H. Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer. 2014;14:52. doi: 10.1186/1471-2407-14-52.
- Dietrich P, Johnson IM, Alli S, Dragatsis I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLOS Genetics. 2017;13:e1006846. doi: 10.1371/journal.pgen.1006846.
- DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS. 2007;104:17204–17209. doi: 10.1073/pnas.0708285104.
- Dogan I, Eickhoff SB, Schulz JB, Shah NJ, Laird AR, Fox PT, Reetz K. Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis. Neurodegenerative Diseases. 2013;12:23–35. doi: 10.1159/000339528.
- Dombeck DA, Graziano MS, Tank DW. Functional clustering of neurons in motor cortex determined by cellular resolution imaging in awake behaving mice. Journal of Neuroscience. 2009;29:13751–13760. doi: 10.1523/JNEUROSCI.2985-09.2009.
- Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nature Genetics. 2000;26:300–306. doi: 10.1038/81593.
- Duan W, Jiang M, Jin J. Metabolism in HD: still a relevant mechanism? Movement Disorders. 2014;29:1366–1374. doi: 10.1002/mds.25992.
- Frank S. Treatment of Huntington's disease. Neurotherapeutics. 2014;11:153–160. doi: 10.1007/s13311-013-0244-z.
- Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, Sharma V, Pooters T, Nagpal A, Skalecka A, Truong VT, Wiebe S, Groves IA, Jafarnejad SM, Chapat C, McCullagh EA, Gamache K, Nader K, Lacaille JC, Gkogkas CG, Sonenberg N. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nature Medicine. 2017;23:674–677. doi: 10.1038/nm.4335.
- Grienberger C, Konnerth A. Imaging calcium in neurons. Neuron. 2012;73:862–885. doi: 10.1016/j.neuron.2012.02.011.
- Griesche N, Schilling J, Weber S, Rohm M, Pesch V, Matthes F, Auburger G, Krauss S. Regulation of mRNA translation by MID1: a common mechanism of expanded CAG repeat RNAs. Frontiers in Cellular Neuroscience. 2016;10:226. doi: 10.3389/fncel.2016.00226.
- Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. PNAS. 2005;102:5820–5825. doi: 10.1073/pnas.0501507102.
- HD iPSC Consortium Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nature Neuroscience. 2017;20:648–660. doi: 10.1038/nn.4532.
- Heng MY, Tallaksen-Greene SJ, Detloff PJ, Albin RL. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. Journal of Neuroscience. 2007;27:8989–8998. doi: 10.1523/JNEUROSCI.1830-07.2007.
- Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, Sequedo MD, Peiró C, Millán JM, Vázquez-Manrique RP. Metformin intake associates with better cognitive function in patients with Huntington's disease. PLoS One. 2017;12:e0179283. doi: 10.1371/journal.pone.0179283.
- Hollis F, van der Kooij MA, Zanoletti O, Lozano L, Cantó C, Sandi C. Mitochondrial function in the brain links anxiety with social subordination. PNAS. 2015;112:15486–15491. doi: 10.1073/pnas.1512653112.
- Holmström MH, Iglesias-Gutierrez E, Zierath JR, Garcia-Roves PM. Tissue-specific control of mitochondrial respiration in obesity-related insulin resistance and diabetes. American Journal of Physiology-Endocrinology and Metabolism. 2012;302:E731–E739. doi: 10.1152/ajpendo.00159.2011.
- Humbert S. Is Huntington disease a developmental disorder? EMBO Reports. 2010;11:899. doi: 10.1038/embor.2010.182.
- Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540:230–235. doi: 10.1038/nature20587.
- Jin J, Gu H, Anders NM, Ren T, Jiang M, Tao M, Peng Q, Rudek MA, Duan W. Metformin protects cells from mutant huntingtin toxicity through activation of AMPK and modulation of mitochondrial dynamics. NeuroMolecular Medicine. 2016;18:581–592. doi: 10.1007/s12017-016-8412-z.
- Jin YN, Johnson GV. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. Journal of Bioenergetics and Biomembranes. 2010;42:199–205. doi: 10.1007/s10863-010-9286-7.
- Keiser MS, Kordasiewicz HB, McBride JL. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Human Molecular Genetics. 2016;25:R53–R64. doi: 10.1093/hmg/ddv442.
- Kerr JN, Greenberg D, Helmchen F. Imaging input and output of neocortical networks in vivo. PNAS. 2005;102:14063–14068. doi: 10.1073/pnas.0506029102.
- Kerschbamer E, Biagioli M. Huntington's disease as neurodevelopmental disorder: altered chromatin regulation, coding, and non-coding RNA transcription. Frontiers in Neuroscience. 2015;9:509. doi: 10.3389/fnins.2015.00509.
- Keskin AD, Kekuš M, Adelsberger H, Neumann U, Shimshek DR, Song B, Zott B, Peng T, Förstl H, Staufenbiel M, Nelken I, Sakmann B, Konnerth A, Busche MA. BACE inhibition-dependent repair of Alzheimer's pathophysiology. PNAS. 2017;114:8631–8636. doi: 10.1073/pnas.1708106114.
- Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Köhler A, Glossmann H, Schneider R, Sutherland C, Schweiger S. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. PNAS. 2010;107:21830–21835. doi: 10.1073/pnas.0912793107.
- Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031–1044. doi: 10.1016/j.neuron.2012.05.009.
- Krauss S, Griesche N, Jastrzebska E, Chen C, Rutschow D, Achmüller C, Dorn S, Boesch SM, Lalowski M, Wanker E, Schneider R, Schweiger S. Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nature Communications. 2013;4:1511. doi: 10.1038/ncomms2514.
- Kuznetsov AV, Brandacher G, Steurer W, Margreiter R, Gnaiger E. Isolated rat heart mitochondria and whole rat heart as models for mitochondrial cold ischemia-reperfusion injury. Transplantation Proceedings. 2000;32:45. doi: 10.1016/S0041-1345(99)00869-6.
- Labbadia J, Morimoto RI. Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends in Biochemical Sciences. 2013;38:378–385. doi: 10.1016/j.tibs.2013.05.003.
- Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O'Regan A, Queller S, Frost C, Leavitt BR, Dürr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC, TRACK-HD Investigators Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington's Disease. Journal of the International Neuropsychological Society. 2016;22:595–608. doi: 10.1017/S1355617716000321.
- Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Human Molecular Genetics. 2001;10:137–144. doi: 10.1093/hmg/10.2.137.
- Lu XH, Yang XW. "Huntingtin holiday": progress toward an antisense therapy for Huntington's disease. Neuron. 2012;74:964–966. doi: 10.1016/j.neuron.2012.06.001.
- Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR. Metformin therapy in a transgenic mouse model of Huntington's disease. Neuroscience Letters. 2007;411:98–103. doi: 10.1016/j.neulet.2006.10.039.
- Mehler MF, Gokhan S. Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat. Trends in Neurosciences. 2000;23:599–605. doi: 10.1016/S0166-2236(00)01705-7.
- Menalled L, El-Khodor BF, Patry M, Suárez-Fariñas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiology of Disease. 2009;35:319–336. doi: 10.1016/j.nbd.2009.05.007.
- Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Metformin: its emerging role in oncology. Hormones. 2011;10:5–15. doi: 10.14310/horm.2002.1288.
- Miller JE, Ayzenshtat I, Carrillo-Reid L, Yuste R. Visual stimuli recruit intrinsically generated cortical ensembles. PNAS. 2014;111:E4053–E4061. doi: 10.1073/pnas.1406077111.
- Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. Journal of Clinical Investigation. 2011;121:493–499. doi: 10.1172/JCI45691.
- Molero AE, Arteaga-Bracho EE, Chen CH, Gulinello M, Winchester ML, Pichamoorthy N, Gokhan S, Khodakhah K, Mehler MF. Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease. PNAS. 2016;113:5736–5741. doi: 10.1073/pnas.1603871113.
- Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. PNAS. 2002;99:10417–10422. doi: 10.1073/pnas.152161099.
- Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, Tabrizi SJ, Bates GP. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. Scientific Reports. 2017;7:1307. doi: 10.1038/s41598-017-01510-z.
- Nguyen HP, Kobbe P, Rahne H, Wörpel T, Jäger B, Stephan M, Pabst R, Holzmann C, Riess O, Korr H, Kántor O, Petrasch-Parwez E, Wetzel R, Osmand A, von Hörsten S. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Human Molecular Genetics. 2006;15:3177–3194. doi: 10.1093/hmg/ddl394.
- Paxinos G. Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. 2nd ed XXV. San Diego: Academic Press; 2001.
- Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews Neuroscience. 2013;14:708–721. doi: 10.1038/nrn3570.
- Predict-HD Investigators of the Huntington Study Group. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biological Psychiatry. 2007;62:1341–1346. doi: 10.1016/j.biopsych.2006.11.034.
- PREDICT-HD investigators of the Huntington Study Group. Harrington DL, Rubinov M, Durgerian S, Mourany L, Reece C, Koenig K, Bullmore E, Long JD, Paulsen JS, Rao SM. Network topology and functional connectivity disturbances precede the onset of Huntington's disease. Brain. 2015;138:2332–2346. doi: 10.1093/brain/awv145.
- Putcha D, Brickhouse M, O'Keefe K, Sullivan C, Rentz D, Marshall G, Dickerson B, Sperling R. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. Journal of Neuroscience. 2011;31:17680–17688. doi: 10.1523/JNEUROSCI.4740-11.2011.
- Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 2014;10:204–216. doi: 10.1038/nrneurol.2014.24.
- Rubinsztein DC, Orr HT. Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: there may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile. BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology. 2016;38:977–980. doi: 10.1002/bies.201600048.
- Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. PNAS. 2013;110:2366–2370. doi: 10.1073/pnas.1221891110.
- Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997;90:549–558. doi: 10.1016/S0092-8674(00)80514-0.
- Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, Misra K, Cheng SH, Shihabuddin LS. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Human Gene Therapy. 2014;25:461–474. doi: 10.1089/hum.2013.200.
- Stosiek C, Garaschuk O, Holthoff K, Konnerth A. In vivo two-photon calcium imaging of neuronal networks. PNAS. 2003;100:7319–7324. doi: 10.1073/pnas.1232232100.
- Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH. Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011;25:1–14. doi: 10.1037/a0020937.
- Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018;14:133–150. doi: 10.1038/nrneurol.2017.188.
- Tallaksen-Greene SJ, Crouse AB, Hunter JM, Detloff PJ, Albin RL. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience. 2005;131:843–852. doi: 10.1016/j.neuroscience.2004.10.037.
- Vázquez-Manrique RP, Farina F, Cambon K, Dolores Sequedo M, Parker AJ, Millán JM, Weiss A, Déglon N, Neri C. AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. Human Molecular Genetics. 2016;25:1043–1058. doi: 10.1093/hmg/ddv513.
- Walter C, Clemens LE, Müller AJ, Fallier-Becker P, Proikas-Cezanne T, Riess O, Metzger S, Nguyen HP. Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro. Neuropharmacology. 2016;108:24–38. doi: 10.1016/j.neuropharm.2016.04.041.
- Wilson H, De Micco R, Niccolini F, Politis M. Molecular imaging markers to track Huntington's Disease Pathology. Frontiers in Neurology. 2017;8:11. doi: 10.3389/fneur.2017.00011.
- Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M. Default-mode network changes in preclinical Huntington's disease. Experimental Neurology. 2012;237:191–198. doi: 10.1016/j.expneurol.2012.06.014.
- Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 2000;101:57–66. doi: 10.1016/S0092-8674(00)80623-6.
- Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. The Journal of Neuroscience. 2003;23:2193–2202. doi: 10.1523/JNEUROSCI.23-06-02193.2003.
- Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. Journal of Neuroscience. 2004;24:8853–8861. doi: 10.1523/JNEUROSCI.2978-04.2004.
Source: PubMed